General
Preferred name
NAFAMOSTAT
Synonyms
Nafamostat Mesylate ()
Nafamostat (hydrochloride) ()
FUT-175 ()
nafamostat mesilate, Mucokinetica ()
Nafamostat (mesylate) ()
Futhan, FUT-175 ()
Nafamostat hydrochloride ()
Nafamostat mesilate (FUT-175) ()
Ronastat ()
Nafamostat dimethanesulfonate ()
Nafamostat mesilate ()
P&D ID
PD013543
CAS
82956-11-4
81525-10-2
80251-32-7
Tags
available
covalent binder
drug
drug candidate
Approved by
PMDA
Drug indication
Coronavirus Disease 2019 (COVID-19)
Middle East Respiratory Syndrome (MERS)
Pancreatitis
Acute kidney injury
Sepsis
COVID-19
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall[1][2][3][4].
PRICE 40
DESCRIPTION Nafamostat is a guanidinobenzoate-containing inhibitor, with activity against a range of serine proteases. Some data is attached to nafamostat mesylate (PubChem CID 5311180). (GtoPdb)
DESCRIPTION Noncompetitive PCAF/p300 inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Serine protease inhibitor, inhibits tryptase (Tocriscreen Plus)
DESCRIPTION Nafamostat mesylate (FUT-175), a synthetic serine protease inhibitor, has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. (TargetMol Bioactive Compound Library)
DESCRIPTION Nafamostat is a broad spectrum serine protease inhibitor and kallikrein inhibitor. It inhibits blood coagulation and used as an anticoagulant. It is also a possible complement inhibitor. It is mainly used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. It is formulated with HCl salt due to its basic tendencies. (BOC Sciences Bioactive Compounds)
DESCRIPTION Nafamostat hydrochloride is a synthetic serine protease inhibitor. It is used as an anticoagulant. It is similar to Tranilast. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
2
Compound Sets
31
AdooQ Bioactive Compound Library
A10617
BOC Sciences Bioactive Compounds
nafamostat-cas-81525-10-2-item-77863
nafamostat-hydrochloride-cas-80251-32-7-item-419922
Cayman Chemical Bioactives
14837
ChEMBL Drugs
CHEMBL3989553
CHEMBL273264
Concise Guide to Pharmacology 2017/18
4262
Concise Guide to Pharmacology 2019/20
4262
Concise Guide to Pharmacology 2021/22
4262
Concise Guide to Pharmacology 2023/24
4262
CovBinderInPDB
CBR005089
CBR006380
CBR007172
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB12598
DrugCentral
1867
DrugCentral Approved Drugs
1867
DrugMAP
DM8D6O2
DMU1XOD
DrugMAP Approved Drugs
DMU1XOD
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EOS101487
Guide to Pharmacology
4262
JUMP-Target 1 Compound Set
4413
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL273264
Mcule NIBR MoA Box Subset
MCULE-8038009111
MedChem Express Bioactive Compound Library
HY-B0190A
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
Nafamostat-mesylate
TargetMol Bioactive Compound Library
T2392
Tocris Bioactive Compound Library
3081
Tocriscreen Plus
3081
ZINC Tool Compounds
ZINC000003874467
External IDs
69
Properties
(calculated by RDKit )
Molecular Weight
347.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
5
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
3
cLogP
2.65
TPSA
138.07
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.21
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Target
Ser/Thr Protease
Apoptosis
SARS-CoV
Serine Protease
ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7
ASIC1
Flavivirus
NF-κB
TNF Receptor
Apoptosis related,COVID-19,SARS-CoV,Serine Protease
Pathway
Metabolic Enzyme/Protease
Anti-infection
Microbiology/virology
Proteases/Proteasome
NF-¦ÊB
Primary Target
Other Proteases
MOA
Inhibitor
Tryptase Inhibitors
Serine Protease inhibitor
Member status
member
Indication
anticoagulent
Therapeutic Class
Antiviral Agents
Solubility
10 mM in DMSO
Source data